HTB homepage • Conference reports • Articles by subject • Subscribe 3 April 2004 Contents Editorial Volume 5 number 3 April 2004 Treatment alerts Risk factors for severe, life-threatening and fatal hepatotoxicity with nevirapine Conference reports 11th Conference on Retroviruses and Opportunistic Infections (CROI) Drug levels can persist for more than two weeks after stopping efavirenz Race affects absorption and clearance of efavirenz Triple PI interactions: atazanavir increases saquinavir levels in ritonavir-boosted once-daily combination Triple PI interactions: fosamprenavir and Kaletra interaction is difficult to overcome Ribavirin (RBV) does not alter intracellular levels of AZT, 3TC or d4T COLATE study shows no clinical benefit from continuing 3TC to maintain M184V mutation Studies of new pipeline drugs Little benefit seen for treatment during acute infection Summary of resistance studies at Retrovirus Update on peripheral neuropathy in HIV-infection Smoking marijuana provides analgesic effect on HIV neuropathy Two D:A:D updates: cardiovascular risk from HAART, and predictors of hypertension and changes in blood pressure Low-dose rHGH maintains reductions in abdominal fat for 60 weeks HTB homepage • Conference reports • Articles by subject • Subscribe
